Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halozyme Therapeutic (NQ: HALO ) 59.05 -1.38 (-2.28%) Streaming Delayed Price Updated: 10:38 AM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 185,226 Open 60.56 Bid (Size) 59.06 (2) Ask (Size) 59.13 (1) Prev. Close 60.43 Today's Range 58.99 - 61.56 52wk Range 32.83 - 65.53 Shares Outstanding 142,334,900 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts Today 8:01 EDT Via Benzinga NASDAQ:HALO is showing good growth, while it is not too expensive. September 19, 2024 Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. Via Chartmill Performance YTD +57.93% +57.93% 1 Month -3.54% -3.54% 3 Month +14.53% +14.53% 6 Month +48.63% +48.63% 1 Year +58.57% +58.57% More News Read More NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. September 19, 2024 Via Chartmill Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire (HALO) - Analyzing Halozyme Therapeutics's Short Interest September 13, 2024 Via Benzinga Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. September 13, 2024 Via Chartmill NASDAQ:HALO is not too expensive for the growth it is showing. August 29, 2024 Via Chartmill Top 2 Health Care Stocks That May Plunge In August August 26, 2024 Via Benzinga How Is The Market Feeling About Halozyme Therapeutics? August 20, 2024 Via Benzinga Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know September 13, 2024 Via Benzinga NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. August 28, 2024 Via Chartmill Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 Via Investor's Business Daily Looking for growth without the hefty price tag? Consider NASDAQ:HALO. August 08, 2024 Via Chartmill Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. August 08, 2024 Via Chartmill (HALO) - Analyzing Halozyme Therapeutics's Short Interest August 01, 2024 Via Benzinga Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics August 01, 2024 Via Benzinga Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. July 22, 2024 Via Chartmill HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 Via InvestorPlace Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts August 06, 2024 Via Investor's Business Daily Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 August 06, 2024 Via Investor's Business Daily NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. August 05, 2024 Via Chartmill 3 Biotech Stocks on Track for 50% Returns (or More) by 2028 August 04, 2024 Via InvestorPlace Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 Via Investor's Business Daily Beam Therapeutics Stock Earns RS Rating Jump To 85 July 24, 2024 Via Investor's Business Daily 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition July 18, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
